source
- FDA issues third warning letter to Empower Pharmacy over GLP-1 weight-loss treatmentsThe U.S. Food and Drug Administration sent a formal warning letter to Empower Pharmacy, a compounder based in Houston, concerning its GLP-1 weight-loss products. The notice marks the company's thi…
- Federal AI Initiative Aims to Improve Chronic Heart Failure Care, Pending Doctor and Patient AcceptanceA new federal program will test artificial‑intelligence tools in the management of chronic heart‑failure patients. The initiative is designed to explore how AI can support diagnosis, monitoring and…